| G0000 |
G250.A2 |
1 mg |
$39.40 |
| |
C45H72N14O12 FW 1001.16 |
2 mg |
$66.30 |
| |
|
5 mg |
$118.30 |
| |
|
|
|
| G0048 |
GABA, Gamma-amino butyric acid |
10 g |
$16.50 |
| |
g-Amino-n-butyric acid |
25 g |
$24.60 |
| |
C4H9NO2 FW 103.12 [56-12-2] |
100 g |
$41.10 |
| |
The major inhibitory neurotransmitter in the mammalian central nervous system. |
|
|
| |
Chebib M, Johnston GA. Clin Exp Pharmacol Physiol 26:937-40 (1999). |
|
|
| |
|
|
|
| G0106 |
Gabapentin |
10 mg |
$62.20 |
| |
Neurontin |
50 mg |
$248.40 |
| |
C9H17NO2 FW 171.24 [60142-96-3] |
250 mg |
$896.90 |
| |
An antiepileptic agent that is chemically related to g-aminobutyric acid (GABA). |
|
|
| |
Goa KL, Sorkin EM. Drugs. 46:409-27 (1993). |
|
|
| |
|
|
|
| G0144 |
Galactosamine hydrochloride |
500 mg |
$41.10 |
| |
C6H14ClNO5 FW 215.63 |
1 g |
$51.60 |
| |
An aminosugar isolated from chondroitin sulfate. |
5 g |
$245.30 |
| |
It is an inducer of apoptosis in hepatocytes. |
|
|
| |
Leist M, Gantner F, Jilg S, Wendel A. J Immunol. 154:1307-16 (1995). |
|
|
| |
Itokazu Y, Segawa Y, Inou N, Omata T. Biol Pharm Bull. 22:127-30 (1999). |
|
|
| |
|
|
|
| G0146 |
Galanin, human |
1 mg |
$358.40 |
| |
C139H210N42O43 FW 3157.44 |
|
|
| |
Galanin is a neuropeptide found to be associated with Alzheimer's disease. |
|
|
| |
Counts SE, Perez SE, Ginsber SD et al. Mol Interv. 3:137-56 (2003). |
|
|
| |
|
|
|
| G0147 |
Galanin, porcine |
1 mg |
$358.40 |
| |
C146H213N43O40 FW 3210.55 [88813-36-9] |
|
|
| |
|
|
|
| |
|
|
|
| G0148 |
Galanin, rat |
1 mg |
$401.40 |
| |
C141H211N43O41 FW 3164.48 |
|
|
| |
|
|
|
| |
|
|
|
| G0246 |
Galanthamine Hydrobromide |
5 mg |
$27.70 |
| |
C17H21NO3.HBr FW 368.27 [1953-04-4] |
25 mg |
$75.90 |
| |
A cholinesterase inhibitor used in the treatment of Alzheimer's disease. |
100 mg |
$262.20 |
| |
Potentiates nicotine-evolved increases in intracellular Ca2+ and [3H]noradrenaline release. |
|
|
| |
Sweeney JE, Puttfarcken PS, Coyle JT. Pharmacol Biochem Behav. 34:129-37 (1989). |
|
|
| |
Lilienfeld S. CNS Drug Rev. 8:159-76 (2002). |
|
|
| |
Dajas-Bailador FA, Heimala K, Wonnacott S. Mol Pharmacol. 64:1217-26 (2003). |
|
|
| |
|
|
|
| G0044 |
Galantide |
0.5 mg |
$136.20 |
| |
C104H151N25O26S FW 2199.58 |
1 mg |
$231.20 |
| |
Acts as a reversible antagonist to the neuropeptide galanin. |
2.5 mg |
$408.60 |
| |
Bartfai T, Bedecs K, Land T et al. Proc Natl Acad Sci U S A. 88:10961-10965 (1991). |
|
|
| |
Lindskog S, Ahren B, Land T, et al. Eur J Pharmacol. 210:183-188 (1992). |
|
|
| |
|
|
|
| G0145 |
Gallic acid |
10 g |
$20.30 |
| |
3,4,5-Trihydroxybenzoic acid [149-91-7] |
100 g |
$30.20 |
| |
C7H6O5 FW 170.12 |
500 g |
$77.60 |
| |
Induces apoptosis in human lung cancer cells. It is cytotoxic to PC14 AND MKN45 human |
|
|
| |
cancer cell lines. |
|
|
| |
Ohno Y, Fukuda K, Takamura G, Toyota M. Anticancer Drugs.10:845-51 (1999). |
|
|
| |
Lee IR, Yang MY. Arch Pharm Res. 17:476-9 (1994). |
|
|
| |
|
|
|
| G0152 |
Ganciclovir |
50 mg |
$116.50 |
| |
C9H13N5O4 FW 255.23 [82410-32-0] |
100 mg |
$215.00 |
| |
Nucleoside analog used to disrupt DNA replication. |
|
|
| |
Matthews T, Boehmw R. Rev. Infect Dis 10 Suppl 3:S490-4 (1988). |
|
|
| |
|
|
|
| G0175 |
Gastric Inhibitory Peptide (GIP), human |
0.5 mg |
$136.20 |
| |
C226H338N60O66S FW 4983.64 |
1 mg |
$231.20 |
| |
|
2.5 mg |
$408.60 |
| |
|
|
|
| G0180 |
Gastrin I, human |
1 mg |
$136.20 |
| |
C130H204N38O31S2 FW 2098.22 |
2 mg |
$231.20 |
| |
A growth factor for established tumors that stimulates the growth of gastric |
5 mg |
$408.60 |
| |
mucosa. |
|
|
| |
Watson SA, Morris TM, Varro A et al. Gut. 45:812-817 (1999). |
|
|
| |
Konda Y, Kamimura H, Yokota H et al. Am J Physiol. 277:G773-G784 (1999). |
|
|
| |
|
|
|
| G0178 |
Gastrin, chicken |
0.5 mg |
$236.50 |
| |
C190H265N47O51S1 FW 4055.58 |
1 mg |
$401.40 |
| |
|
2.5 mg |
$709.60 |
| |
|
|
|
| G0179 |
Gastrin-1, rat |
0.5 mg |
$136.20 |
| |
C94H128N22O31S2 FW 2126.32 |
1 mg |
$231.20 |
| |
|
2.5 mg |
$408.60 |
| |
|
|
|
| G0181 |
Gastrin Releasing Peptide, human |
1 mg |
$268.80 |
| |
C130H204N38O31S2 FW 2859.40 |
|
|
| |
GRP regulates tumor proliferation and metastasis in a number of gastrointestinal cancers. |
|
|
| |
Levine L, Licci JA 3rd, Townsend CM Jr et al. J Am Coll Surg. 196:898-904 (2003). |
|
|
| |
|
|
|
| G0182 |
Gastrin Releasing Peptide, porcine |
1 mg |
$268.80 |
| |
C126H198N38O31S2 FW 2805.40 |
|
|
| |
|
|
|
| |
|
|
|
| G0278 |
Gatifloxacin |
500 mg |
$65.40 |
| |
C19H22FN3O4 FW 375.39 [112811-59-3] |
1 g |
$99.90 |
| |
A fluoroquinolone that has an 8-methoxy group, which contributes to its |
5 g |
$304.90 |
| |
selectivity as an antibacterial agent. |
|
|
| |
Fukuda H, Kishii R. Takei M, Hosaka M. Antimicrob Agents Chemother. 45:1645-53 (2001). |
|
|
| |
|
|
|
| G0096 |
G-A-Y |
5 mg |
$43.00 |
| |
C14H19N3O5 FW 309.18 |
10 mg |
$73.50 |
| |
|
25 mg |
$129.00 |
| |
|
|
|
| G1721 |
Gefitinib |
100 mg |
$68.00 |
| |
C22H24ClFN4O3 FW 446.90 [184475-35-2] |
250 mg |
$120.00 |
| |
A drug used in the treatment of certain types of cancer. Acting in a similar manner |
1 g |
$350.00 |
| |
to erlotinib, gefitinib selectively targets the mutant proteins in malignant cells. |
|
|
| |
Boehrer, S. Biochemical Pharmacology (2008), 76(11), 1417-1425. |
|
|
| |
|
|
|
| G1646 |
Geldanamycin |
100 µg |
$28.00 |
| |
C29H40N2O9 FW 560.64 [30562-34-6] |
5 x 100 µg |
$109.80 |
| |
A benzoquinoid ansamycin antibiotic having antitumor activities. Suppresses |
1 mg |
$156.80 |
| |
DNA replication by inhibiting c-myc gene expression in lymphoblastoma L5178Y cells. |
|
|
| |
It inhibits tyrosine kinases and induces increased p53 protein involved in cell-cycle arrests |
|
|
| |
of human ovarian tumor cells. It inhibits the 90 kDa heat shock protein that regulates |
|
|
| |
cell signal transduction, telomerase activity, and induces apoptosis. |
|
|
| |
Yamaki H, Iguchi-Ariga SM, Ariga H. J Antibiot (Tokyo). 42:604-10 (1989). |
|
|
| |
McIlwrath AJ, Brunton VG, Brown R. Cancer Chemother Pharmacol. 37:423-8 (1996). |
|
|
| |
Villa R, Folini M, Porta CD et al. Carcinogenesis. 24:851-9 (2003). |
|
|
| |
Kim S, Kang J, Hu W. Int J Cancer. 103:352-9 (2003). |
|
|
| |
|
|
|
| G1745 |
Gemcitabine Hydrochloride |
25 mg |
$109.80 |
| |
C9H12ClF2N3O4 FW 299.66 [122111-03-9] |
100 mg |
$280.00 |
| |
A deoxycytidine-analogue antimetabolite that has demonstrated activity against |
|
|
| |
non-small cell lung cancer, pancreatic cancer, ovarian cancer, and breast cancer. |
|
|
| |
Hui YF, Reitz J. Am J Health Syst Pharm. 54:162-170 (1997). |
|
|
| |
|
|
|
| G1749 |
Gemfibrozil |
5 g |
$45.60 |
| |
2,2-Dimethyl-5-(2,5-xylyoxy) valeric acid |
25 g |
$151.90 |
| |
C15H22O3 FW 250.33 [25812-30-0] |
|
|
| |
A hyperlipidemic agent that elevates plasma HDL and lowers triglycerides and LDL by |
|
|
| |
stabilizing apoA-I mRNA transcripts. It was found to inhibit inducible nitric oxide synthase |
|
|
| |
by inhibiting the activation of nuclear factor-kappaB, activator protein-1 and CCAAT/enhancer- |
|
|
| |
binding proein beta. |
|
|
| |
Goto D, Okimoto T, Ono M et al. Arter. Throm Vas Biol. 17:2707-1712 (1997). |
|
|
| |
Pahan K, Jana M, Liu X et al. J Biol Chem. 277:45984-45991 (2002). |
|
|
| |
|
|
|
| G1650 |
Geniposide |
10 mg |
$88.10 |
| |
C17H24O10 FW 388.37 |
25 mg |
$189.80 |
| |
Natural product isolated from the fruit of Gardenia. It was found to induce |
100 mg |
$607.20 |
| |
increased activity of phase II detoxifying enzymes, inhibit tumor promotion, and |
|
|
| |
induce apoptosis in rat C6 glioma cells. |
|
|
| |
Wang CJ, Wang SW, Lin JK. Cancer Letters. 60:95-102 (1991). |
|
|
| |
Lee MJ, Hsu JD, Wang CJ. Anticancer Res. 15:411-416 (1995). |
|
|
| |
Chang YC, Tseng TH, Lee MJ. Chemico-Biol Interactions. 141: 243-257 (2002). |
|
|
| |
|
|
|
| G1652 |
Genistein |
100 mg |
$52.60 |
| |
C15H10O5 FW 270.2 [446-72-0] |
500 mg |
$190.20 |
| |
An isoflavone with anticancer, antiproliferative, and chemopreventive effects. |
1 g |
$303.40 |
| |
It induces cell differentiation and inhibits metabolic activation of benzo[a]pyrene. |
|
|
| |
Chae Y-H, Ho DK, Cassady JM et al. Chem. Biol. Int. 82:181-193 (1992). |
|
|
| |
Jing Y, Waxman S. Anticancer Res. 15:1147-1152 (1995). |
|
|
| |
|
|
|
| G1653 |
Genistin |
1 mg |
$39.20 |
| |
C21H20O10 FW 432.38 [529-59-9] |
5 mg |
$134.40 |
| |
Glucoside of Genistein exhibiting cytotoxic effects in vitro. Genistin is an inhibitor |
|
|
| |
of protein tyrosine kinase and DNA toposomerase. |
|
|
| |
Shaoquan et. al. J of Nutri. 129: 1291-1297 (1999). |
|
|
| |
|
|
|
| G1658 |
Gentamycin sulfate |
500 mg |
$32.90 |
| |
[1405-41-0] |
1 g |
$49.30 |
| |
Antibiotic from fermentation. |
5 g |
$205.10 |
| |
Black J et al. Antimicrob. Ag. Chemother. 138-137 (1963). |
10 g |
$327.90 |
| |
|
|
|
| G1869 |
Geranylgeraniol |
25 mg |
$84.00 |
| |
C20H34O FW 290.5 [24034-73-9] |
100 mg |
$240.20 |
| |
A polyprenyl alcohol found to induce apoptosis in various human tumor cell lines. |
|
|
| |
Ohizumi H, Masuda Y, Yoda M et al. Abticancer Res. 17:1051-7 (1997). |
|
|
| |
Yaguchi M, Miyazawa K, Katagiri T et al. Leukemia 11:779-87 (1997). |
|
|
| |
|
|
|
| G2368 |
G-F-R |
5 mg |
$43.00 |
| |
C17H26N6O4 FW 387.4 |
10 mg |
$73.50 |
| |
|
25 mg |
$129.00 |
| |
|
|
|
| G2868 |
Ghrelin, human |
1 mg |
$250.90 |
| |
C149H249N47O42 FW 3370.9 |
5 mg |
$860.20 |
| |
A gastric peptide hormone that regulates growth hormone secretion. It has been shown to |
|
|
| |
exert MAPK-mediated proliferogenic and antiapoptotic effects in cultured human adrenal |
|
|
| |
zona glomerulosa cells. |
|
|
| |
Mazzocchi G, Neri G, Rucinski M et al. Peptides. 25:1269-77 (2004). |
|
|
| |
|
|
|
| G2869 |
Ghrelin, rat |
1 mg |
$250.90 |
| |
C147H245N45O42 FW 3314.8 |
5 mg |
$860.20 |
| |
|
|
|
| |
|
|
|
| G2870 |
GHRF (1-44), human |
0.5 mg |
$207.90 |
| |
C215H358N72O66S1 FW 5039.7 [83930-13-6] |
1 mg |
$353.00 |
| |
|
2.5 mg |
$623.60 |
| |
|
|
|
| |
|
|
|
| G2874 |
GHRF, rat |
0.5 mg |
$236.50 |
| |
C225H361N77O66S FW 5232.93 |
1 mg |
$401.40 |
| |
|
2.5 mg |
$709.60 |
| |
|
|
|
| |
|
|
|
| G2871 |
GHRF, bovine |
0.5 mg |
$236.50 |
| |
C220H366N72O66S1 FW 5107.88 |
1 mg |
$401.40 |
| |
|
2.5 mg |
$709.60 |
| |
|
|
|
| |
|
|
|
| G2873 |
GHRF, ovine |
0.5 mg |
$164.90 |
| |
C221H368N72O66S1 FW 5121.9 |
1 mg |
$279.60 |
| |
|
2.5 mg |
$494.60 |
| |
|
|
|
| |
|
|
|
| G2872 |
GHRF, mouse |
0.5 mg |
$236.50 |
| |
C220H365N69O64S1 FW 5032.85 |
1 mg |
$401.40 |
| |
|
2.5 mg |
$709.60 |
| |
|
|
|
| |
|
|
|
| G2968 |
GHRP-2 |
0.5 mg |
$64.50 |
| |
C45H54O6N9 FW 818.0 |
1 mg |
$109.30 |
| |
|
2.5 mg |
$193.50 |
| |
|
|
|
| G2969 |
GHRP-6 |
1 mg |
$64.50 |
| |
C46H56N12O6 FW 873.04 |
2 mg |
$109.30 |
| |
|
5 mg |
$193.50 |
| |
|
|
|
| G3352 |
Ginkgolic acid (13:0) |
1 mg |
$392.00 |
| |
C20H32O3 FW 320.47 |
5 mg |
$896.00 |
| |
Isolated from ginkgo sarcotestas, Ginkgolic acid inhibits growth of tumor cells and |
|
|
| |
normal cells in vitro. |
|
|
| |
Yang X, Qian Z, Chen J et al. Zhong Yao Cai. 27:40-42 (2004). |
|
|
| |
|
|
|
| G3353 |
Ginkgolic acid (15:1) |
1 mg |
$168.00 |
| |
Romanicardic acid |
5 mg |
$560.00 |
| |
C22H34O3 FW 346.50 |
|
|
| |
Natural product isolated from ginkgo biloba. |
|
|
| |
|
|
|
| G3351 |
Ginkgolic acids Mixture |
5 mg |
$112.00 |
| |
|
25 mg |
$425.60 |
| |
|
|
|
| G3354 |
Ginkgolide A |
10 mg |
$36.10 |
| |
C20H24O9 FW 408.40 [15291-75-5] |
25 mg |
$80.60 |
| |
One of a group of cage molecules isolated from the leaves of the Ginkgo biloba |
50 mg |
$116.50 |
| |
tree. A highly active platelet-activating factor (PAF) antagonist. A potential |
|
|
| |
therapeutic agent in a variety of immunological and inflammatory disorders. |
|
|
| |
Braquet P, Esanu A, Buisine E et al. Medicinal Res. Reviews 1:295-355 (1991). |
|
|
| |
Wada K, Sasaki K, Miura K et al. Biol. Pharm. Bull. 16:210-212 (1993). |
|
|
| |
|
|
|
| G3355 |
Ginkgolide B |
10 mg |
$62.90 |
| |
C20H24O10 FW 424.40 [15291-77-7] |
25 mg |
$147.10 |
| |
One of a group of cage molecules isolated from the leaves of the Ginkgo biloba |
50 mg |
$268.60 |
| |
tree. A highly active platelet-activating factor (PAF) antagonist. A potential |
|
|
| |
therapeutic agent in a variety of immunological and inflammatory disorders. |
|
|
| |
Braquet P, Esanu A, Buisine E et al. Medicinal Res. Reviews. 11:295-355 (1991). |
|
|
| |
Brochet B, Guinot P, Orgozo JM et al. Psychiatry. 58:360-362 (1995). |
|
|
| |
Cheng D, Chen W. Chin. Med. J. 109:881-884 (1996). |
|
|
| |
|
|
|
| G3356 |
Ginkgolide AB |
25 mg |
$40.40 |
| |
A mixture of Ginkgolide A and Ginkgolide B. |
50 mg |
$75.50 |
| |
Braquet P, Esanu A, Buisine E et al. Medicinal Res. Reviews 11:295-355 (1991). |
|
|
| |
|
|
|
| G3357 |
Ginkgolide C |
10 mg |
$121.50 |
| |
C20H24O11 FW 440.40 |
25 mg |
$265.80 |
| |
Natural product from Ginkgo Biloba. |
50 mg |
$455.40 |
| |
|
|
|
| |
|
|
|
| |
|
|
|
| G3359 |
Ginkgolide J |
1 mg |
$168.00 |
| |
C20H24O10 FW 424.40 [107438-79-9] |
5 mg |
$616.00 |
| |
Found in Ginkgo biloba, Ginkgolide J was found to reduce apoptotic damage in cultured |
|
|
| |
chick embryonic neurons. |
|
|
| |
Ahlemeyer B, Krieglstein J. Pharmacopsychiatry. 36 Suppl 1:S8-14 (2003). |
|
|
| |
|
|
|
| G3358 |
Ginkgolides |
100 mg |
$86.00 |
| |
Mixture of Ginkgolides A, B and C. |
500 mg |
$268.60 |
| |
|
1 g |
$358.20 |
| |
|
|
|
| |
Ginsenosides (See page 17 for more information) |
|
|
| |
Ginsenosides are active ingredients isolated from the oriental herb, ginseng. They are |
|
|
| |
steroidal saponins. Many ginsenosides have been found to have anticancer properties |
|
|
| |
against tumor cell lines and tumor growth. Others have been shown to have CNS |
|
|
| |
effects ranging from protecting neurons from ischemic damage to preventing |
|
|
| |
scopolamine-induced memory deficits. The following is a complete list of ginsenosides |
|
|
| |
related compounds. |
|
|
| |
|
|
|
| G3460 |
Ginsenoside F1 |
1 mg |
$60.80 |
| |
C36H62O9 FW 638.87 |
5 mg |
$151.90 |
| |
|
10 mg |
$265.80 |
| |
|
|
|
| |
|
|
|
| |
|
|
|
| G3461 |
Ginsenoside F2 |
1 mg |
$60.80 |
| |
C42H72O14 FW 801.01 |
5 mg |
$151.90 |
| |
|
10 mg |
$265.80 |
| |
|
|
|
| |
|
|
|
| |
|
|
|
| G3462 |
Ginsenoside F3 |
1 mg |
$60.80 |
| |
C41H70O13 FW 770.99 |
5 mg |
$151.90 |
| |
|
10 mg |
$265.80 |
| |
|
|
|
| |
|
|
|
| |
|
|
|
| G3454 |
Ginsenoside Rb1 |
5 mg |
$103.30 |
| |
C54H92O23 FW 1109.29 [41753-43-9] |
10 mg |
$174.70 |
| |
|
25 mg |
$341.60 |
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| G3553 |
Ginsenoside Rb2 |
5 mg |
$189.80 |
| |
C53H90O22 FW 1079.27 [11021-13-9] |
10 mg |
$326.50 |
| |
|
25 mg |
$652.70 |
| |
|
|
|
| |
|
|
|
| |
|
|
|
| G3554 |
Ginsenoside Rb3 |
5 mg |
$117.40 |
| |
C53H90O22 FW 1079.27 [68406-26-8] |
10 mg |
$200.10 |
| |
|
25 mg |
$400.20 |
| |
|
|
|
| |
|
|
|
| |
|
|
|
| G3455 |
Ginsenoside Rc |
1 mg |
$60.80 |
| |
C53H90O22 FW 1079.27 [11021-14-0] |
5 mg |
$151.90 |
| |
|
10 mg |
$265.80 |
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| G3456 |
Ginsenoside Rd |
1 mg |
$60.80 |
| |
C48H82O18 FW 947.15 [52705-93-8] |
5 mg |
$151.90 |
| |
|
10 mg |
$265.80 |
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| G3457 |
Ginsenoside Re |
1 mg |
$60.80 |
| |
C49H84O17 FW 947.18 [52286-59-6] |
5 mg |
$151.90 |
| |
|
10 mg |
$265.80 |
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| G3458 |
Ginsenoside Rg1 |
5 mg |
$103.30 |
| |
C42H72O14 FW 801.01 [22427-39-0] |
10 mg |
$174.70 |
| |
|
25 mg |
$341.60 |
| |
|
|
|
| |
|
|
|
| |
|
|
|
| G3459 |
Ginsenoside Rg2 |
1 mg |
$60.80 |
| |
C42H72O13 FW 785.01 [52286-74-5] |
5 mg |
$151.90 |
| |
|
10 mg |
$265.80 |
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| G3556 |
Ginsenoside Rg3 |
5 mg |
$109.30 |
| |
C42H72O13 FW 785.01 [14197-60-5] |
10 mg |
$189.80 |
| |
|
25 mg |
$379.50 |
| |
|
|
|
| |
|
|
|
| |
|
|
|
| G3557 |
Ginsenoside Rh1 |
5 mg |
$129.10 |
| |
C36H62O9 FW 638.87 [63223-86-9] |
10 mg |
$220.20 |
| |
|
25 mg |
$440.30 |
| |
|
|
|
| |
|
|
|
| G3453 |
Ginsenoside Rh2 |
1 mg |
$53.20 |
| |
C36H62O8.H2O FW 640.89 |
5 mg |
$129.10 |
| |
Is a plant glycoside with a dammarane skeloton resembling a steroid skeleton. It |
10 mg |
$220.20 |
| |
has anti- proliferation, differentiation and chemopreventive effects in certain |
25 mg |
$440.30 |
| |
cancer cell types. It was found to induce apoptosis in rat glioma C6Bu-1 cells, |
|
|
| |
human neuroblastoma SK-N-BE 2 cells and human ovarian cancer cell lines. |
|
|
| |
Oh M, Choi YH, Choi S, Chung H et al. Int J Oncol. Int 14:869-75 (1999). |
|
|
| |
Kim Ys, Jin Sh, Lee YH et al. Arch Parm Res. 22:448-53 (1999). |
|
|
| |
Kim YS, jin SH, Lee YH et al. Arch Pharm Res. 23:518-24 (2000). |
|
|
| |
Nakata H, Kikuchi Y, Tode T et al. Jpn J Cancer Res. 89:733-40 (1998). |
|
|
| |
|
|
|
| G3463 |
Ginsenoside X |
1 mg |
$72.90 |
| |
C48H82O19 FW 963.15 |
5 mg |
$189.80 |
| |
|
10 mg |
$318.80 |
| |
|
|
|
| |
|
|
|
| |
|
|
|
| N5778 |
Notoginsenoside R1 |
5 mg |
$106.30 |
| |
C47H80O17 FW 917.13 |
10 mg |
$182.20 |
| |
|
25 mg |
$356.80 |
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| P0253 |
Panaxadiol |
5 mg |
$109.30 |
| |
C30H52O3 FW 460.73 |
10 mg |
$189.80 |
| |
|
25 mg |
$379.50 |
| |
|
|
|
| |
|
|
|
| |
|
|
|
| P0254 |
Panaxatriol |
5 mg |
$109.30 |
| |
C30H52O4 FW 476.73 |
10 mg |
$189.80 |
| |
|
25 mg |
$379.50 |
| |
|
|
|
| |
|
|
|
| |
|
|
|
| P6957 |
Protopanaxadiol |
5 mg |
$121.50 |
| |
C30H52O3 FW 460.73 |
10 mg |
$212.60 |
| |
|
25 mg |
$417.50 |
| |
|
|
|
| |
|
|
|
| P6958 |
Protopanaxatriol |
5 mg |
$121.50 |
| |
C30H52O4 FW 476.73 |
10 mg |
$212.60 |
| |
|
25 mg |
$417.50 |
| |
|
|
|
| |
|
|
|
| P7318 |
Pseudoginsenoside F11 |
5 mg |
$129.10 |
| |
C48H82O19 FW 963.15 |
10 mg |
$220.20 |
| |
|
25 mg |
$440.30 |
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
Ginsenoside X (See ginsenosides) |
|
|
| |
|
|
|
| G4532 |
Gliclazide |
1 g |
$27.70 |
| |
C15H21N3O3S FW 323.41 |
5 g |
$77.30 |
| |
Inhibits monocyte adhesion in type 2 diabetes and increases free radical |
10 g |
$117.40 |
| |
scavenging. |
|
|
| |
Holmes B, Heel R, Brogden RN et al. Drugs 27:301-27 (1984). |
|
|
| |
O'Brien RC, Luo M, Balazs N, Mercuri J. J Diabetes Complications. 14:201-6 (2000). |
|
|
| |
|
|
|
| G4535 |
Glimepiride |
500 mg |
$34.50 |
| |
C24H34N4O5S FW 490.62 [93479-97-1] |
1 g |
$55.20 |
| |
A sulfonylurea hypoglycemic agent acts with the lowest ratio of insulin release to |
5 g |
$227.70 |
| |
glucose release when compared with other sulfonylureas. It increases cardiac glucose |
|
|
| |
uptake by enhancing protein expression of glucose transports -1 and -4 independent of |
|
|
| |
insulin responsiveness. |
|
|
| |
Bahr M, von Holtey M, Muller G, Eckel. J. Endocrinology. 136:2547-53 (1995). |
|
|
| |
Schiekofer S, Rudofsky G Jr, Andrassy M et al. Diabetes Obes Metab. 5:251-61 (2003). |
|
|
| |
|
|
|
| G4434 |
Gliotoxin |
1 mg |
$50.40 |
| |
C13H14N2O4S2 FW 326.39 [67-99-2] |
5 mg |
$168.00 |
| |
A sulfur containing antibiotic. Possesses immunosuppressive properties as it |
10 mg |
$302.40 |
| |
may suppress and cause apoptosis. Acts as an inhibitor of farnesyl transferase. |
|
|
| |
Hur Jung-Mu. Journal of cellular biochemistry (2008), 104(6), 2174-84. |
|
|
| |
|
|
|
| G4634 |
Glipizide |
500 mg |
$52.50 |
| |
C21H27N5O4S FW 445.54 [29094-61-9] |
1 g |
$96.70 |
| |
An oral hypoglycemic agent that enhances insulin secretion by inhibiting its |
5 g |
$414.00 |
| |
metabolic clearance. It blocks ATP-dependent K+ channels in pancreatic b cells |
|
|
| |
and brain GABA containing neurons resulting in insulin release. |
|
|
| |
Barzilai N, Groop PH, Groop, DeFronzo RA. Acta Diabetol. 32:273-8 (1995). |
|
|
| |
Brogden RN, Heel RC, Pakes GE et al. Drugs. 18:329-53 (1979). |
|
|
| |
Lamensdorf I, He L, Nechushtan A et al. Eur J Pharmacol. 388:147-54 (2000). |
|
|
| |
|
|
|
| G4480 |
Glucagon, human |
1 mg |
$295.70 |
| |
C153H225N43O49S FW 3482.78 |
|
|
| |
An essential hormone that increases cAMP in hepatocytes, shown to reduce iNOS expression. |
|
|
| |
Harbrecht BG, Perpetua M, Fulmer M et al. Shock. 22:157-62 (2004). |
|
|
| |
|
|
|
| G4479 |
Glucagon (19-29), human |
1 mg |
$35.80 |
| |
C61H89N15O18S FW 1352.54 |
2 mg |
$60.90 |
| |
|
5 mg |
$107.50 |
| |
|
|
|
| G4481 |
Glucagon-Like Peptide I (7-36), amide, human |
0.5 mg |
$136.20 |
| |
C149H229N40O45 FW 3297.7 |
1 mg |
$231.20 |
| |
Effector in the hormonal control of insulin secretion. |
2.5 mg |
$408.60 |
| |
Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian RC. Nature. 304:368-371 (1983). |
|
|
| |
|
|
|
| G4482 |
Glucagon-Like Peptide I (7-37); GLP-1 (7-37) |
0.5 mg |
$179.20 |
| |
C151H226N40O46 FW 3337.73 |
1 mg |
$304.60 |
| |
|
2.5 mg |
$537.60 |
| |
|
|
|
| G4483 |
Glucagon-Like Peptide II, human |
0.5 mg |
$164.90 |
| |
C171H266N48O56S FW 3922.38 |
1 mg |
$279.60 |
| |
|
2.5 mg |
$494.60 |
| |
|
|
|
| |
|
|
|
| G4484 |
Glucagon-Like Peptide II, rat |
0.5 mg |
$207.90 |
| |
C166H256N44O56S FW 3796.22 |
1 mg |
$353.00 |
| |
|
2.5 mg |
$623.60 |
| |
|
|
|
| |
|
|
|
| G4485 |
[Ala19] Glucagon-Like Peptide II, rat |
0.5 mg |
$207.90 |
| |
C165H254N44O55S FW 3766.2 |
1 mg |
$353.00 |
| |
|
2.5 mg |
$623.60 |
| |
|
|
|
| |
|
|
|
| G4518 |
Glucaric acid, calcium salt |
25 g |
$47.00 |
| |
D-saccharic acid, calcium salt. |
100 g |
$134.40 |
| |
C6H8O8Ca.4H2O. FW 320.3 [5793-89-5] |
|
|
| |
It is a nontoxic, natural compound. One of its derivatives 1,4-GL increases detoxification |
|
|
| |
of carcinogens and tumor promoters/ progressors by inhibiting b-glucuronidase |
|
|
| |
and preventing hydrolysis of their glucuronides. |
|
|
| |
Walaszek Z, Szemraj J, Narog M et al. Cancer Detect Prev. 21:178-90 (1997). |
|
|
| |
Abou-Issa H, Moeschberger M, el-Masry W et al. Anticancer Res. 15:805-10 (1995). |
|
|
| |
|
|
|
| G4580 |
Glucosamine hydrochloride |
25 g |
$13.90 |
| |
C6H13NO5.HCl FW 215.6 [66-84-2] |
100 g |
$27.70 |
| |
Hydrochloride salt of glucosamine, an effective treatment for osteoarthritis pain. |
500 g |
$107.60 |
| |
Lu F, Guo H. Wei Sheng Yan Jiu. 32:594-7 (2003). |
|
|
| |
|
|
|
| G4581 |
Glucosamine sulfate |
100 g |
$33.60 |
| |
C6H13NO5.1/2H2SO4 FW 228.2 [29031-19-4] |
500 g |
$98.60 |
| |
An antiarthritic agent isolated from chitin. |
1 kg |
$170.10 |
| |
Setnikar I, Pacini MA, Revel L. Arzneimittelforschung. 41:542-545 (1991). |
|
|
| |
|
|
|
| G4596 |
Glycidamide |
10 mg |
$98.80 |
| |
C3H5NO2 FW 87.08 |
25 mg |
$159.50 |
| |
An epoxide metabolite of acrylamide. It is neurotoxic and carcinogenic. |
100 mg |
$493.40 |
| |
Costa LG, Deng H, Callema CJ, Bergmark E. Toxicology 98:151-161 (1995). |
|
|
| |
|
|
|
| G4597 |
18 b-Glycyrrhetinic Acid |
5 g |
$58.10 |
| |
Enoxolone |
10 g |
$97.10 |
| |
C30H46O4 FW 470.68 m.p. 325-328oC [471-53-4] |
25 g |
$194.20 |
| |
The aglycone of the triterpenoid Glyccyrrhizic acid, with potent |
|
|
| |
antitumor promoting activity. |
|
|
| |
Kelloff GJ, Boone CW, Crowell JA et al. Cancer Epidemiol. Biomarkers Prev. 3:85-98 (1994). |
|
|
| |
|
|
|
| G4598 |
Glycyrrhizic acid, ammonium salt, trihydrate |
10 g |
$25.90 |
| |
Glycyrrhizin |
25 g |
$50.70 |
| |
C42H65NO16.3H2O FW 894.03 m.p. 209-2110C [53956-04-0] |
|
|
| |
A triterpenoid saponin with antiproliferative activity. Found to inhibit |
|
|
| |
arylamine-N-acetyltransferase in Klebsiella pneumoniae. |
|
|
| |
Lo HH, Yen YS, Hsieh SE, Chung JG. J. Appl. Toxicol. 17:385-390 (1997). |
|
|
| |
|
|
|
| G5752 |
Gonadorelin Acetate |
Please inquire |
|
| |
C55H75N17O13 FW 1182.3 [71447-49-9] |
|
|
| |
An LHRH agonist. Diagnosis of the hypothalamic-pituitary-gonadal axis function |
|
|
| |
and cryptorchism. Use in reproduction medicine and ovarian follicular cysts |
|
|
| |
(veterinary medicine). |
|
|
| |
|
|
|
| G5772 |
Goserelin Acetate |
Please inquire |
|
| |
C59H84N18O14 FW 1269.4 [145781-92-6] |
|
|
| |
Goserelin acetate is a potent LHRH agonist. For the treatment of advanced hormone- |
|
|
| |
dependent breast cancer, advanced hormone-dependent prostate cancer, endometriosis |
|
|
| |
and uterus myoma. Use in reproduction medicine. |
|
|
| |
|
|
|
| G5874 |
Gossypol |
25 mg |
$33.20 |
| |
C30H30O8 FW 518.55 [303-45-7] |
100 mg |
$89.70 |
| |
A potential male anti-fertility agent from cotton that exhibits a wide spectrum of |
250 mg |
$179.40 |
| |
toxicity. It was found to have cytotoxic effects on human cancer cell lines. It is |
|
|
| |
a potent telomerase inhibitor. |
|
|
| |
Nadakavukaren MJ, Sorensen RH, Tone JN. Cell Tissue Res. 204:293-6 (1979). |
|
|
| |
Sakesena SK, Salmonsen R, Lau IF, Chang MC. Contraception. 24:203-14 (1981). |
|
|
| |
Tuszynski GP, Cossu G. Cancer Res. 44:768-71 (1984). |
|
|
| |
Mego M. Bratisl Lek Listy. 103:378-81 (2002). |
|
|
| |
|
|
|
| G6000 |
gp38 |
1 mg |
$236.50 |
| |
C133H209N41O38S2 FW 3054.53 |
2 mg |
$401.40 |
| |
|
5 mg |
$709.60 |
| |
|
|
|
| |
|
|
|
| G6368 |
G-P-R |
5 mg |
$43.00 |
| |
C13H24N6O4 FW 328.18 |
10 mg |
$73.50 |
| |
|
25 mg |
$129.00 |
| |
|
|
|
| G6400 |
G-Q |
5 mg |
$43.00 |
| |
C7H13N3O4 FW 203.2 |
10 mg |
$73.50 |
| |
|
25 mg |
$129.00 |
| |
|
|
|
| G6802 |
Granisetron |
25 mg |
$39.20 |
| |
C18H24N4O FW 312.20 [109889-09-0] |
100 mg |
$112.00 |
| |
This compound has been used to successfully treat post operative nausea. |
500 mg |
$448.00 |
| |
Fujii Y, Clin Drug Investig. 26(8):427-37.(2006) |
|
|
| |
Rubenstein EB, Slusher BS, Rojas C, Navari RM. Cancer J; 12(5):341-7 (2006) |
|
|
| |
|
|
|
| G6803 |
Granuliberin R |
1 mg |
$50.20 |
| |
C69H103N19O14 FW 1422.71 |
2 mg |
$86.00 |
| |
A histamine-releasing peptide originally isolated from the skin of Rana rugosa |
5 mg |
$150.50 |
| |
that induces mast cell degranulation. |
|
|
| |
Kozakiewicz M, Godlewski A. Cell Mol Biol Lett. 8:727-734 (2003). |
|
|
| |
Lechago J, Crawford BG, Walsh JH. Neuroscience. 12:329-337 (1984). |
|
|
| |
|
|
|
| G6817 |
Green tea polyphenols |
10 g |
$62.90 |
| |
Extracts of green tea. Inhibitors of chemical carcinogenesis. |
20 g |
$107.50 |
| |
Wang Z Y, Khan WA, Bickers D, Mukhtar H. Carcinogenesis. 10:411-5 (1989). |
100 g |
$402.90 |
| |
Yamane T, Hagiwar, N, Tateishi M et al. Jpn. J. Cancer Res. 82:1336-39 (1991). |
|
|
| |
|
|
|
| G6856 |
Growth Hormone Releasing Factor, human |
1 mg |
$461.70 |
| |
C215H358N72O66S FW 5039.70 |
|
|
| |
|
|
|
| |
|
|
|
| G8101 |
Guaifenesin |
25 g |
$18.00 |
| |
C10H14O4 FW 198.22 [93-14-1] |
100 g |
$48.40 |
| |
An expectorant reported to have muscle relaxant and sedative activity. It is |
500 g |
$138.00 |
| |
often used as anesthetic animal surgery. |
|
|
| |
Muir WW, Skarda RT, Sheehan W. Am J Vet Res. 39:1274-8 (1978). |
|
|
| |
Dicpinigaitis PV, Gayle YE. Chest. 124:2178-81 (2003). |
|
|
| |
|
|
|
| G8103 |
Guanylin, human |
0.5 mg |
$207.90 |
| |
C58H87N15O21S4 FW 1458.68 |
1 mg |
$353.00 |
| |
An endogenous activator of intestinal guanylate cyclase. |
2.5 mg |
$623.60 |
| |
Wiegand RC, Kato J, Currie MG. Biochem Biophys Res Commun. 185:812-817(1992). |
|
|
| |
|
|
|
| G8104 |
Guanylin, rat, mouse |
0.5 mg |
$207.90 |
| |
C60H90N16O22S4 FW 1515.74 |
1 mg |
$353.00 |
| |
|
2.5 mg |
$623.60 |
| |
|
|
|